Biotech company with a special focus on developing psychedelic medicines to treat addiction Entheon BioMedical Corp. (CNSX: ENBI) has unveiled a psychedelics genetic test kit fully developed by its wholly owned subsidiary HaluGen Life Sciences Inc.
This goes down as the first test kit of this kind developed in the psychedelics industry. Entheon says this kit is now available for purchase in Canada.
Halugen runs a psychedelic pre-screening unit, a DNA testing using the kit gives genetic, personal and familial data which assists in identifying the psychedelic therapy needed by the patient.
After capturing the DNA data, medical professionals are equipped with data which helps in bettering therapy patient care and reducing side effects and risk associated with psychedelic therapies.
The company says this kit will be available in the United States market in the next few months. At the moment, Entheon is looking into various partnership deals aiming at building brand awareness.
